ExoDiscovery Detect Pancreatic - Accurate and Fast Early Detection of Pancreatic Cancer

ExoDiscovery Detect Pancreatic finds molecular signals associated with early-stage pancreatic cancer, with 97% accuracy in preliminary validation studies¹.

Join the Early Access Program

Be among the firsts to offer ExoDiscovery Detect Pancreatic

Get Early Access

High Clinical Impact

According to the American Cancer Society, patients diagnosed at Stage I have a 15× higher 5-year survival rate².

Detection of molecular signals linked to early pancreatic cancer changes in high-risk individuals, supporting timely clinical decisions

Minimally Invasive

The test requires a standard blood draw, of which only 20μL of plasma is used for analysis.

Convenient at-home blood draw through a trusted third-party service.

24-Hour Results

Molecular test results within 24 hours of sample receipt at our laboratory.

Decreased patient anxiety and faster clinical decision-making.

Learn More

Get Early Access to ExoDiscovery Detect

ExoDiscovery's revolutionary technology provides unprecedented insights into cancer at the molecular level—enabling earlier detection and more precise treatment monitoring with 24-hour results.

Fill this form to request early access to ExoDiscovery Detect Pancreatic.

Whether you have a question, need support, or just want to learn more about our technology, our team is here to help.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Unparalleled High Detection Capability

In clinical validation studies (n=101)¹, ExoDiscovery Detect demonstrated exceptionally high analytical sensitivity, detecting cancer-associated signals at concentrations far lower than conventional blood-based biomarker tests.

ExoDiscovery Detect

Speed

24-hour turnaround time

Stages I-II Detection

94% Sensitivity

99.9% Specificity

Sample Size

Minimal 20μL plasma

Cost

Competitive test pricing

Comparable Screening

Speed

7-14 day waiting period

Stages I-II Detection

<40% Sensitivity

~99.5% Specificity

Sample Size

10-20mL required

Cost

Higher testing expenses

Comprehensive Biomarker Coverage: ExoDiscovery Detect identifies molecular signals biomarkers that are individually observed in a high percentage³ of pancreatic cancer cases, including KRAS mutations, EGFR expression, and CA19-9.

A positive result should be followed with confirmatory diagnostic procedures as recommended by a healthcare professional. A negative result reduces — but does not eliminate — the possibility of pancreatic cancer.

1. Accuracy is calculated as the proportion of true positive and true negative results among all tested samples. Data on file. Internal case-control, blind, retrospective study with n=101. Study results may not reflect real-world outcomes. Also see: Elizabeth Maria Clarissa, Sumit Kumar, Juhee Park, Mamata Karmacharya, In-Jae Oh, Mi-Hyun Kim, Jeong-Seon Ryu, and Yoon-Kyoung Cho. Digital Profiling of Tumor Extracellular Vesicle-Associated RNAs Directly from Unprocessed Blood Plasma. ACS Nano 2025 19 (5), 5526-5538. Sensitivity is defined as the percentage of actual positives correctly identified by the test. Specificity is defined as the percentage of actual negatives correctly identified by the test. Public data suggest conventional methods in comparable screening show <40% sensitivity in early-stage disease.

2. American Cancer Society. Cancer Facts & Figures 2025. Atlanta: American Cancer Society; 2025.
‍
3. KRAS mutations are present in ~90–95% of pancreatic ductal adenocarcinoma (PDAC) cases⁴, EGFR is overexpressed in ~40–70%⁵, and CA19-9 is elevated in ~70–90%⁶. Prevalence refers to individual biomarker expression, not necessarily their co-occurrence.
‍
4. Fan Z, Fan K, Yang C, Huang Q, Gong Y, Cheng H, Jin K, Liu C, Ni Q, Yu X, Luo G. Critical role of KRAS mutation in pancreatic ductal adenocarcinoma. Transl Cancer Res 2018.
‍
5. Andrei-Florian Stoica, Chao-Hui Chang, Siim Pauklin, Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells, Trends in Pharmacological Sciences, Volume 41, Issue 12, 2020.
‍
6. Guopei Luo, Kaizhou Jin, Shengming Deng, He Cheng, Zhiyao Fan, Yitao Gong, Yunzhen Qian, Qiuyi Huang, Quanxing Ni, Chen Liu, Xianjun Yu, Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Volume 1875, Issue 2, 2021.

How It Works

The test must be ordered by a licensed healthcare provider.

Step 1

Test Ordering

After the test is ordered, a small blood sample is conveniently collected at home by a mobile phlebotomy partner.

Step 2

Rapid Processing

Blood samples are received overnight and immediately processed at our CLIA-certified laboratory in Austin, TX.

Step 3

Results in 24 Hours

Test results are posted securely on our cloud platform within 24 hours of sample receipt at our laboratory.

ExoDiscovery Detect is a physician-ordered, CLIA-certified laboratory-developed test (LDT) for the detection of pancreatic cancer-associated molecular signals in high-risk individuals. It has not been cleared or approved by the FDA. This test is not intended to replace diagnostic procedures such as imaging or biopsy. Clinical judgment should guide interpretation and patient care decisions.

‍

Join the Early Access Program

Be among the firsts to offer ExoDiscovery Detect Pancreatic

Get Early Access

Early Detection for Pancreatic Cancer